BIND Therapeutics
BIND Therapeutics: A new way of targeting disease
We believe ACCURINS® represent the next stage in the evolution of targeted therapies and nanomedicine.
ACCURINS® are polymeric nanoparticles that incorporate a therapeutic payload and are designed to have prolonged circulation within the bloodstream, enable targeting of the diseased tissue or cells, and provide for the controlled and timely release of the therapeutic payload.

Prolonged circulation. We design ACCURINS® with a stealth and protective layer that enables them to circulate within the bloodstream for a prolonged period of time, and accumulate at the diseased site before being cleared from the circulatory system.

Targeting. We design ACCURINS® with specific pharmaceutical properties intended to target tumors at three levels: tissue, cellular and molecular. Tissue targeting is achieved by engineering the physical and chemical properties—size, shape and surface properties—of the Accurin to allow it to escape through gaps in the blood vessels surrounding tumors and other disease sites. Cellular targeting is achieved using proprietary targeting ligands on the surface of the Accurin that binds to specific cell surfaces or tissue markers. The specific characteristics of the therapeutic payload may enable molecular targeting within the diseased cells. The following diagram depicts the mechanisms of tissue targeting and cellular targeting.

Controlled and timely release. We design ACCURINS® with specific polymers that provide for the controlled and timely release of the therapeutic payload. Upon administration, the therapeutic payload begins to diffuse through the polymeric matrix. Subsequently, the polymer breaks down to lactic acid, a compound naturally found in the body. If the therapeutic payload releases before the ACCURINS® accumulate at the disease site, the ACCURINS® will be unable to effectively increase drug concentration in the diseased tissue and the anticipated therapeutic impact will be minimized or lost. Similarly, if the therapeutic payload is not released, or releases too slowly, the anticipated therapeutic impact will be lost or minimized and new toxicities may be created. By combining prolonged circulation, triple targeting and controlled and timely release of the therapeutic payload, ACCURINS® have the potential to significantly increase the net clinical benefit associated with the therapeutic payload and result in efficacy and safety currently not achievable through other therapeutic modalities.

BIND's targeted ACCURINS® consist of the following components that are optimized to achieve selective targeting of diseased cells and tissues.

Fluorescence micrograph of ACCURIN™
Fluorescence micrograph showing accumulation of ACCURINS® in the cytosol of a cancer cell. The Accurin nanoparticles contain a red fluorescent dye and the nucleus and cytosol are stained blue and green, respectively. The ACCURINS® are targeted to a cell surface antigen and undergo internalization via receptor-mediated endocytosis.

← Mouse over the component
     names to learn more.